PT-112 in advanced metastatic castrate-resistant prostate cancer (mCRPC), as monotherapy or in combination with PD-L1 inhibitor avelumab: Findings from two phase I studies.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.6_suppl.83
Abstract: 83Background: PT-112, the first pyrophosphate conjugate in Phase I/II clinical development, induces robust immunogenic cell death and is osteotropic, prompting study in mCRPC during Phase I. We rep... read more here.
Keywords: advanced metastatic; phase; metastatic castrate; 112 advanced ... See more keywords